ReviewPostepy dermatologii i alergologii2022
The 2020 update on anaphylaxis in paediatric population.
Review in Postepy dermatologii i alergologii, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 15 citations in OpenAlex.
- Model-Informed Dose Selection of Intranasal Epinephrine in Young Children.Journal of clinical pharmacology · 2026Article
- Management of paediatric anaphylaxis: evaluation of clinical practice according to the 2024 Polish Paediatric Society guidelines.Postepy dermatologii i alergologii · 2026Article
- Pediatric Anaphylaxis in the Emergency Department: From Mechanisms to Personalized Care.Cureus · 2025Review
- Clinical and Treatment Evaluation of Anaphylaxis in Children Aged 0-2 Years: Multicenter Study.Pediatric research · 2025Article
- Impact of Treatment on Rate of Biphasic Reaction in Children with Anaphylaxis.The western journal of emergency medicine · 2025Article
- A reference centre experience in central Anatolia in terms of causes, severity and treatment of childhood anaphylaxis.Northern clinics of Istanbul · 2025Article
- The Timely Administration of Epinephrine and Related Factors in Children with Anaphylaxis.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of the review is to present recent updates on anaphylaxis in paediatric population worldwide. The article summarizes the results of epidemiological studies, diagnostic methods and treatments. We present a new WAO definition of anaphylaxis (2019), which broader criteria excluding dermal symptoms should facilitate faster life-saving adrenaline use. Adrenaline remains the best treatment to manage severe symptoms and to prevent biphasic reactions. There is ongoing effort to increase adrenaline use, such as modified autoinjectors, individual training, and diversified dosing. There are five independent risk factors of lethal anaphylaxis in children, including history of asthma, almost immediate onset of symptoms, unwell appearance, tachycardia and hypotension. We also report improvements in diagnostics, like component-resolved diagnostics, and novel therapies stimulating immunotolerance. We signal the development of ICD-11 with updated coding of anaphylaxis, which corresponds better to clinical observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.